Oregon Public Employees Retirement Fund Has $3.70 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Oregon Public Employees Retirement Fund increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 37.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 19,463 shares of the medical research company’s stock after acquiring an additional 5,271 shares during the period. Oregon Public Employees Retirement Fund’s holdings in IQVIA were worth $3,697,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in IQV. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $515,772,000. Norges Bank bought a new position in shares of IQVIA during the 2nd quarter worth approximately $270,160,000. AQR Capital Management LLC boosted its stake in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC grew its position in IQVIA by 15,755.2% in the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after acquiring an additional 774,681 shares during the period. Finally, Nordea Investment Management AB raised its stake in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after acquiring an additional 606,391 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $242.70 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a 50 day simple moving average of $224.37 and a 200 day simple moving average of $200.77. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.05. The firm has a market cap of $41.33 billion, a P/E ratio of 33.29, a P/E/G ratio of 2.47 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IQV shares. Citigroup upped their target price on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday, October 29th. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and upped their price objective for the stock from $206.00 to $215.00 in a research note on Monday, November 3rd. Evercore ISI lifted their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Finally, Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $249.19.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.